Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Denies Fraudulent Conduct Alleged By U.S. FDA As Rumors Swirl About Daiichi Deal

This article was originally published in PharmAsia News

Executive Summary

Ranbaxy has denied U.S. FDA allegations that it conducted "systematic fraudulent conduct" related to concealing violations of current good manufacturing practices

You may also be interested in...



Talk Of $1 Billion Fine On Ranbaxy By U.S. FDA Dents Stock; Analysts Divided Over Exact Penalty

MUMBAI - Shares of Ranbaxy Laboratories Ltd., listed on the Indian stock exchanges, plunged 6% May 5 to 426 Indian Rupees ($9.48) per share, reacting sharply to a Fortune magazine report that claimed the company may be fined over $1 billion as part of a protracted negotiation and settlement process with U.S. FDA

Talk Of $1 Billion Fine On Ranbaxy By U.S. FDA Dents Stock; Analysts Divided Over Exact Penalty

MUMBAI - Shares of Ranbaxy Laboratories Ltd., listed on the Indian stock exchanges, plunged 6% May 5 to 426 Indian Rupees ($9.48) per share, reacting sharply to a Fortune magazine report that claimed the company may be fined over $1 billion as part of a protracted negotiation and settlement process with U.S. FDA

U.S. Congress Expands Probe Into Ranbaxy’s AIDS Drugs Supplied To Developing Nations

MUMBAI - Four leaders of the U.S. Congressional Committee on Energy and Commerce - John Dingell, Bart Stupak, Joe Barton and John Shimkus have expanded their investigations into U.S. FDA's handling of Ranbaxy's anti-AIDS drugs that are supplied to African and other developing nations as part of the President's Emergency Plan for AIDS Relief program

Related Content

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel